Home > > > > Report Detail

Pandemic Outbreaks in the Past Decade: A BCC Research Overview

Publisher Name :
Date: 02-Jun-2020
No. of pages: 76

Report Includes:

- An overview of the pandemic outbreaks occurred over the last decade (2010-2020)

- Discussion of several serious epidemiological outbreaks, their socioeconomic impact, R&D efforts, treatment and diagnostics, clinical trial landscape, and regulatory and reimbursement landscape

- Data corresponding to number of confirmed cases and reported deaths (globally and country wise) due to various pandemics, including novel coronavirus disease (COVID-19), SARS, MERS, HIV/AIDS, H1N1, Ebola virus etc.

- Correlation of coronavirus (Covid-19) outbreak to previous epidemiological outbreaks in terms of policies and measures of prevention and control, and the lessons learned thereafter

- Insight into key scientific breakthroughs and pipeline products targeting infectious disease treatments, including the novel coronavirus disease and its antibody-based clinical program (antibody to MERS-CoV infection)

Summary

Pandemics are outbreaks of disease that become widespread by transmission of human-to-human infection. Throughout recent history, disease outbreaks and pandemics include Spanish flu, Hong Kong flu, SARS, H7N9, Ebola and Zika. Main features of a pandemic include broad geographic spread, disease movement, novelty, intensity, high attack rates and explosivity, limited population immunity, infectiousness and contagiousness. Pandemics adversely have affected the health of the global population and destabilized the world's economies, social infrastructures, and both geopolitical and natural environments.

Human history has experienced major pandemics such as smallpox, cholera, plague, dengue, AIDS, influenza, extreme acute respiratory syndrome (SARS), West Nile disease and tuberculosis. Influenza pandemics are sporadic yet frequent phenomena. Since the 1500s, influenza pandemics have occurred about three times a century, or about every 10 to 50 years. Three influenza pandemics occurred in the 20th century: 1918 influenza pandemic ("Spanish flu"), 1957-1958 pandemic ("Asian flu"), and the 1968 pandemic ("Hong Kong flu"). Each pandemic harmed human life and economic growth. For example, the 1918 influenza pandemic killed more than 20 million people worldwide. The World Health Organization (WHO) cites that pandemic as the deadliest in world history.

Pandemic Outbreaks in the Past Decade: A BCC Research Overview

Table of Contents

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Analyst's Credentials
Related BCC Research Reports
Chapter 2 Introduction to Pandemics
Pathogenic Microbes and Infectious Diseases: 1973-2019
Factors Contributing to the Emergence of Infectious Diseases
Human Demographics and Behavior
Technology
The Role of Needles
Economic Development and Land Use
International Travel
Microbial Adaptation
Antibiotic Development
Classifying Viral Outbreaks, Epidemics and Pandemics
Current and Potential Epidemics with Pandemic Potential
Current and Potential Pandemics
Current Technologies for Addressing Potential Pandemic Threats
Biological Weapons for Terrorism
The Next Pandemic
Types of Zoonotic Viruses
A Brief History of Global Pandemics
Bubonic Plague (1300 to the Present)
Cholera (1916-1966)
The Spanish Influenza Pandemic (1918)
Asian Flu Pandemic (1957-1958)
HIV/AIDS Pandemic (1980 to the Present)
Influenza A-H1N1 (2009 to the Present)
Malaria (2700 BC to the Present)
Severe Acute Respiratory Syndrome (SARS) (2002-2003)
Tuberculosis (4000 BC to the Present)
Treatments for Infectious Diseases
Prevention
Vaccination
Pharmaceutical Treatments
Chapter 3 H1N1 Influenza (Swine Influenza)
Etiology
Epidemiology
Pathophysiology
Types of Influenza Viruses
Influenza Virus A
Influenza Virus B
Influenza Virus C
Diagnosis and Evaluation
Real-Time Polymerase Chain Reaction
Nucleotide Sequencing
Phylogenetic Analysis
Treatment and Management
Prevention of Swine to Human Viral Transmission
Prevention of Human-to-Human Transmission
Vaccines
Antiviral Treatments
The WHO and Containment for Pandemic Influenza
International Influenza Vaccine Stockpile Orders
Pre-pandemic Vaccination
Biomedical Advanced Research and Development Authority (BARDA)
Antiviral Resistance
Recreated Viruses
Immaterialized Market Risk
Media Coverage and Vaccinations
Pandemic Preparedness Plans
United States
Japan
China
Brazil
United Kingdom
Chapter 4 Ebola Virus Disease
Etiology
Epidemiology
Clinical Manifestations
Diagnosis
Treatment/Management
Supportive Care
Therapeutics
Vaccines and Prevention
Chapter 5 Middle East Respiratory Syndrome
Etiology
Epidemiology
Geographical Distribution
Sources of Infection
Risk Factors and Transmission
Pathophysiology
Clinical Features
Diagnosis
Molecular Diagnostics
Serological Assays
Treatment and Management
Antiviral Agents
Convalescent Plasma
Antibiotic Therapy
Intensive Care Management
New Treatments
Prevention
Advances in Vaccine Development
Priorities: MERS Research, Surveillance, Management, and Control
Establishing a One Health Global Consortium
Priority Studies at the Animal-Human-Environmental Interface
Priority Studies in Human Populations
Priority Studies for Vaccines, Therapeutics, and Rapid Diagnostics
Chapter 6 Coronavirus Disease 2019 (SARS-CoV-2)
Symptoms of COVID-19
COVID-19 Progression
Incubation Period
Epidemiology
Case Fatality Rate (CFR)
Global Confirmed Cases and Confirmed Deaths Due to COVID-19
COVID-19 Research and Development
Diagnostics and Medtech
The Need to Reinvent Ventilators
Clinical Trials on COVID-19
Chapter 7 Lessons Learned from History
Maintaining Essential Healthcare Services
Access to Prevention, Safety Measures, Testing and Treatment
Quarantine and Isolation
International Efforts to Strengthen the Global Outbreak Response System
Africa Centers for Disease Control and Prevention
Coalition for Epidemic Preparedness Innovations
European Medical Corps
Regional Disease Surveillance Systems Enhancement Program
The WHO Global Health Emergency Workforce
The WHO R&D Blueprint
World Bank Pandemic Emergency Financing Facility
Chapter 8 Appendix
Acronyms

List of Tables

Table 1 : Pathogenic Bacteria, Parasites and Viruses, 1973-2019
Table 2 : History of Antibiotic Discovery and Approval, 1935-2013
Table 3 : CDC: Six Phases of Classification of Viral Pandemics
Table 4 : Technologies for Addressing Potential Pandemic Threats
Table 5 : Diseases That Have Been or Can Be Weaponized
Table 6 : Commercial Products of H1N1 Influenzas Diagnostics
Table 7 : Neuraminidase Inhibitor Resistance Testing Results on Samples Collected Since October 1, 2017
Table 8 : Essential and Desirable Elements of the WHO Influenza Pandemic Preparedness Plan
Table 9 : Japan's Action Plan for Influenza Pandemic Preparedness
Table 10 : China's Influenza Pandemic Warning Levels
Table 11 : Brazil's Influenza Pandemic Warning Levels and Action
Table 12 : Ebola Outbreaks Between 1976 and 2014
Table 13 : Clinical Features of Ebola Virus Disease, by Stage
Table 14 : Overview of Investigational Therapeutics Evaluated in Clinical Trials on Ebola Virus Disease During the 2013-2016 West African Outbreak
Table 15 : Key Vaccines with Accelerated Clinical Development During the 2013-2016 Ebola Virus Disease Outbreak
Table 16 : Molecular Diagnostic Tests for MERS-CoV Diagnosis, Single Assays
Table 17 : Molecular Diagnostic Tests for MERS-CoV Diagnosis, Multiplex Assays
Table 18 : Serology Tests for MERS-CoV Diagnosis
Table 19 : Potential Therapies for MERS-CoV Infection
Table 20 : Vaccines in the Pipeline for the Prevention of MERS-CoV Infection
Table 21 : COVID-19 Symptoms by Percentage of Patients
Table 22 : Case Fatality Rate of COVID-19, by Region, March 2020
Table 23 : Case Fatality Rate of COVID-19, by Selected Country
Table 24 : COVID-19: Confirmed Cases and Deaths, by Country, May 14, 2020
Table 25 : COVID-19 Therapeutic Interventions in Development, by Biopharmaceutical Companies in Collaboration
Table 26 : COVID-19 Therapeutics in Development, by Biopharmaceutical Company
Table 27 : COVID-19 Vaccines in Development, by Biopharmaceutical Companies in Collaboration
Table 28 : COVID-19 Vaccines in Development, by Biopharmaceutical Company
Table 29 : Modifiable Breathing Devices Eligible for EUAs, by Company
Table 30 : Number of Clinical Trials on COVID-19, by Phase
Table 31 : Number of Clinical Trials on COVID-19, by Intervention
Table 32 : Clinical Trials on COVID-19, by Country
Table 33 : High-Level Initiatives Established Since the Ebola Crisis
Table 34 : List of Acronyms

List of Figures

Figure 1 : Number of Approved WHO Influenza Centers, by WHO Dedignated Region
Figure 2 : Targeted Pre-pandemic Influenza Vaccine Stockpiles Based on Population Demand for Selected Countries
Figure 3 : Geographical Distribution of Reported Human Infections of MERS-CoV
Figure 4 : Infographic Comparison of CFR and Cases of the Three Major Beta Coronaviruses: MERS, SARS, and COVID-19
Figure 5 : Distribution of Clinical Trials on COVID-19, by Phase
Figure 6 : Distribution of Clinical Trials on COVID-19, by Intervention
Figure 7 : Distribution of Clinical Trials on COVID-19, by Country
Figure 8 : The Role of High-Level Initiatives in Enhancing the Three Main Phases of Global Outbreak Preparedness
  • Global Encephalitis Vaccination Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 102
    According to our LPI (LP Information) latest study, the global Encephalitis Vaccination market size was valued at US$ 1263.1 million in 2023. With growing demand in downstream market, the Encephalitis Vaccination is forecast to a readjusted size of US$ 1875.5 million by 2030 with a CAGR of 5.8% during review period. The research report highlights the growth potential of the global Encephalitis Vaccination market. Encephalitis Vaccination are expected to show stable growth in the future m......
  • Global Avian Influenza Vaccines Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 04-Jan-2024        Price: US 3380 Onwards        Pages: 123
    Market Overview of Global Avian Influenza Vaccines market: According to our latest research, the global Avian Influenza Vaccines market looks promising in the next 5 years. As of 2022, the global Avian Influenza Vaccines market was estimated at USD 933.69 million, and it's anticipated to reach USD 1586.45 million in 2028, with a CAGR of 9.24% during the forecast years. Avian influenza refers to the disease caused by infection with avian (bird) influenza (flu) Type A viruses. ......
  • Global 23-Valent Pneumococcal Polysaccharide Vaccine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 96
    According to our LPI (LP Information) latest study, the global 23-Valent Pneumococcal Polysaccharide Vaccine market size was valued at US$ 1114.7 million in 2023. With growing demand in downstream market, the 23-Valent Pneumococcal Polysaccharide Vaccine is forecast to a readjusted size of US$ 2265.8 million by 2030 with a CAGR of 10.7% during review period. The research report highlights the growth potential of the global 23-Valent Pneumococcal Polysaccharide Vaccine market. 23-Valent P......
  • Global Avian Influenza Vaccines Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 155
    According to our LPI (LP Information) latest study, the global Avian Influenza Vaccines market size was valued at US$ 928.4 million in 2023. With growing demand in downstream market, the Avian Influenza Vaccines is forecast to a readjusted size of US$ 1369 million by 2030 with a CAGR of 5.7% during review period. The research report highlights the growth potential of the global Avian Influenza Vaccines market. Avian Influenza Vaccines are expected to show stable growth in the future mark......
  • Global Encephalitis Vaccination Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 28-Dec-2023        Price: US 3380 Onwards        Pages: 106
    Market Overview of Global Encephalitis Vaccination market: According to our latest research, the global Encephalitis Vaccination market looks promising in the next 5 years. As of 2022, the global Encephalitis Vaccination market was estimated at USD 52963.61 million, and it's anticipated to reach USD 65320.29 million in 2028, with a CAGR of 3.56% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysis......
  • Global Influenza Vaccine Market Research Report 2023
    Published: 28-Dec-2023        Price: US 2900 Onwards        Pages: 96
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Influenza Vaccine market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Sanofi - CSL - GSK - Viatris - AstraZeneca - Hualan Bio - Changchun Institute of Biological - Sinovac - BCHT - Jiangsu G......
  • Global Japanese Encephalitis Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 26-Dec-2023        Price: US 3380 Onwards        Pages: 117
    Market Overview of Global Japanese Encephalitis Vaccine market: According to our latest research, the global Japanese Encephalitis Vaccine market looks promising in the next 5 years. As of 2022, the global Japanese Encephalitis Vaccine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. This report covers a research time span from 2018 to 2028, and presents a deep and comprehensive analysi......
  • Global Influenza Vaccine Industry Research Report, In-depth Analysis of Current Status and Outlook of Key Countries 2023-2028
    Published: 14-Dec-2023        Price: US 3380 Onwards        Pages: 103
    Market Overview of Global Influenza Vaccine market: According to our latest research, the global Influenza Vaccine market looks promising in the next 5 years. As of 2022, the global Influenza Vaccine market was estimated at USD XX million, and it's anticipated to reach USD XX million in 2028, with a CAGR of XX% during the forecast years. Influenza vaccines, also known as flu shots or flu jabs, are vaccines that protect against infection by influenza viruses... ......
  • 2023-2031 Report on Global Influenza Vaccine Market by Player, Region, Type, Application and Sales Channel
    Published: 11-Dec-2023        Price: US 2500 Onwards        Pages: 107
    This report studies the Influenza Vaccine market, covering market size for segment by type (Inactivated Vaccine, Live Attenuated Vaccine, etc.), by application (Pediatric, Adults, etc.), by sales channel (Direct Channel, Distribution Channel), by player (CSL, GSK, Sanofi, Mylan, AstraZeneca, etc.) and by region (North America, Europe, Asia-Pacific, South America and Middle East & Africa). This report provides detailed historical analysis of global market for Influenza Vaccine from......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs